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There are increasing concerns that exposure to unmetabolized folic acid, which results from folic acid intakes that overwhelm the
liver’s metabolic capacity, may be associated with adverse eﬀects. In this paper, we examined the folic acid status of women of
reproductive age in relation to dietary intake and the eﬀect of folic acid supplementation (1.1mg or 5mg). Plasma unmetabolized
folic acid was not signiﬁcantly correlated with folate intake estimated by food frequency questionnaire or biomarkers. The
proportion of women with detectable levels of unmetabolized folic acid increased from 65% to 100% after twelve weeks of
supplementation (P<0.05); however, the increase in concentrations did not reach statistical signiﬁcance and the eﬀect was not
sustained.Moreover,therewerenosigniﬁcantdiﬀerencesbetweenthetwodoses.Thissuggeststhattherearemechanismsbywhich
the body adapts to high folic acid intakes to limit exposure to unmetabolized folic acid.
1.Introduction
The term “folate” describes the group of B vitamers that
share the same vitamin activity based on the parent structure
of folic acid. The parent structure consists of an aromatic
pteridine ring joined by a methylene bridge to para-
aminobenzoic acid (PABA), which in turn is attached to
glutamic acid by a peptide bond (Figure 1)[ 1]. Folate
vitamers diﬀer in the oxidation state of the pteridine ring
and substitution on the N5 and/or N10 nitrogen atoms.
In addition, a polyglutamate tail consisting of up to nine
glutamate residues, each one joined via amide linkage to the
γ-carboxyl group of the preceding residue, may be added
[1, 2].
By convention, the term “folic acid” refers speciﬁcally to
the fully oxidized and most stable form of the vitamin that is
used in supplements and fortiﬁed foods.
Biologically, these groups of vitamins are critical in DNA
synthesis and repair, and as cofactors in biological reactions
involving folate sources. Folate exists naturally in foods as
reduced folate polyglutamate conjugates. In addition, folic
acid is added as a fortiﬁcant to certain foods. As of 2007,
ﬁfty-two countries worldwide had national regulations man-
dating folic acid fortiﬁcation of wheat ﬂour [3]. Folic acid is
also found in supplements and multivitamins.
In general, the bioavailability of folic acid is higher than
that of the naturally occurring food folates. Under fasting
conditions, the bioavailability of folic acid approaches 100%
[4]. When consumed with food, folic acid (either supple-
mental or as a fortiﬁcant) is about 85% bioavailable [4]. The
bioavailability of naturally occurring food folates depends
on whether folate is present primarily as a monoglutamate
or polyglutamate (with the former being more bioavailable)
andthepresenceorabsenceofdietaryandnondietaryfactors
that can facilitate or inhibit folate absorption; on average, it
is estimated to be 50%, although it can be as high as 60 to
90% from some fruits and vegetables [5].
Neural tube defects (NTDs) are congenital malforma-
tionsproducedbyfailureoftheneuraltubetoformandclose
properly during embryonic development. The most com-
montypesofNTDsincludespinabiﬁdaandanencephaly[6].
A relationship between folate deﬁciency and malforma-
tions of the central nervous system was ﬁrst suggested in the
1960s by Smithells et al. [7].2 Obstetrics and Gynecology International
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Figure 1: Structure of folic acid [1]. The three parts of the parent
structure include 2-amino-4-oxo-pteridine, p-aminobenzoic acid,
and glutamic acid. Substitutions (one-carbon groups) occur at the
N5 and/or N10 positions.
To clarify the issue, the Medical Research Council of
the United Kingdom initiated a multicentre, double-blind,
randomized controlled trial (the “MRC Vitamin Study”)
to evaluate the eﬀect of folic acid with or without other
vitamins on the rate of NTD recurrence among women
who had a previous pregnancy complicated by an NTD
[8]. Among 1195 informative pregnancies, the prevalence
of NTDs among women allocated to receive folic acid was
1.0%, compared to 3.5% among women in the other groups.
Thus folic acid reduced the risk of NTD recurrence by 72%
(relative risk, RR, 0.28; 95% conﬁdence interval (CI), 0.12–
0.71). The eﬀect of the “other vitamins” on the risk of NTD
recurrence was nonsigniﬁcant (RR 0.80; 95% CI, 0.32–1.72).
In parallel to the MRC Vitamin Study, a single-centre,
double-blind, randomized controlled trial (the “Hungarian
randomized controlled trial”) was conducted to evaluate the
eﬀect of multivitamin supplementation on ﬁrst occurring
NTDs. There were no NTDs among 2104 pregnancies in
the multivitamin/mineral group (P = 0.029). The protective
eﬀect of the multivitamin (containing 0.8mg of folic acid)
o nﬁ r s to c c u r r e n tN T D sw a se s t i m a t e dt ob e9 0 %[ 9].
In contrast to natural food folates, folic acid is a non-
c o e n z y m a t i cf o r mo ff o l a t e .F o l i ca c i dm e t a b o l i s mi n v o l v e s
conversion of folic acid to coenzymatic tetrahydrofolate
derivatives, primarily 5-CH3-H4PteGlu. The ﬁrst and rate-
limiting step is catalyzed by DHFR, which reduces folic
acid to H2PteGlu (and subsequently to H4PteGlu) [10].
The expression and activity of DHFR in human liver is
relatively low, such that oral doses greater than 260 to 280μg
can saturate the hepatic metabolic capacity, resulting in the
appearance of “unmetabolized” folic acid in plasma [11–13].
With single doses, however, folic acid is rapidly cleared from
plasma through a combination of uptake into peripheral
tissues and renal excretion [14]. On the other hand, two
studies have demonstrated the presence of detectable levels
of unmetabolized folic acid in fasting plasma samples after
eightto14weeksofsupplementationwith400μg/dayoffolic
acid [15, 16]. This suggests that daily ingestion of more than
400μg of folic acid saturates not only hepatic DHFR activity,
but also cellular uptake and renal clearance mechanisms.
There is much debate as to whether exposure to unme-
tabolized folic acid poses a health risk [17]. Theoretically,
folic acid could interfere with normal folate metabolism
through competition with reduced, coenzymatic folates
for transporters, binding proteins, and folate-dependent
enzymes [18–20]. For instance, both folic acid and H2PteGlu
are substrates for DHFR. Although the aﬃnity of DHFR
for H2PteGlu is higher than its aﬃnity for folic acid, in
the presence of high concentrations of folic acid, folic acid
could competitively inhibit the conversion of H2PteGlu
to H4PteGlu [19]. As neither folic acid nor H2PteGlu is
metabolically active, this could theoretically create an intra-
cellular folate deﬁciency [19]. Another study observed a
downregulation of folate transporters in intestinal and renal
epithelial cells cultured in growth media that were oversup-
plemented with folic acid [20]. Although it remains to be
seen whether these in vitro eﬀects also occur in vivo, the
potential implications of disturbed folate metabolism are
wide-ranging; it is, therefore, critical that we gain a better
understanding of the pharmacokinetics and pharmacody-
namics of unmetabolized folic acid.
At present, there is no conclusive evidence that exposure
to unmetabolized folic acid causes adverse health eﬀects.
However, potential concerns (i.e., those that appear to be
uniquely associated with high folic acid intakes) include neg-
ative eﬀects on vitamin B12 deﬁciency, cancer development,
immune function, and epigenetic regulation [21].
The objectives of the present study were twofold.
(1) To examine the relationship between plasma concen-
tration of unmetabolized folic acid and (a) dietary
folic acid and total folate intake and (b) plasma and
r e db l o o dc e l lt o t a lf o l a t ec o n c e n t r a t i o n .
(2) To examine the eﬀect of folic acid supplementation
on fasting plasma concentrations of unmetabolized
folic acid.
2.MaterialsandMethods
2.1. Study Population. The blood samples and dietary data
presented herein were collected as part of a prospective,
randomized, open-label trial of 30 weeks of daily supple-
mentation with 1.1mg or 5mg of folic acid as part of
a prenatal/postpartum vitamin-mineral supplement [22].
Participants were recruited through posters displayed at the
Hospital for Sick Children (Toronto, ON) and at designated
locations on the St. George campus of the University of
Toronto, advertisement in the Hospital for Sick Children
newsletter, online advertisements published on the Hospital
for Sick Children and Motherisk websites, and word-of-
mouth. Motherisk is a clinical, research, and teaching pro-
gram aﬃliated with the University of Toronto that provides
evidence-based information on the safety of medications,
infections, and other exposures during pregnancy and
lactation.
All participants were healthy women between the ages of
18 and 45 at the time of study enrollment. Eligibility was
assessed during an initial telephone or in-person interview.
Potential participants were screened for the following condi-
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(i) Use of folic acid supplements or multivitamin sup-
plements containing folic acid in the six months
preceding study enrollment.
(ii) Previous pregnancy in which an NTD was detected
(iii) Family history of NTDs.
(iv) Concurrent use of medications known to aﬀect folate
status (e.g., antiseizure medications, folate antago-
nists, and oral contraceptives).
(v) Allergyorhypersensitivitytoanyoftheingredientsin
PregVit or PregVit-Folic5.
The protocol for the trial was approved by the Research
Ethics Board at The Hospital for Sick Children. Eligible
participants provided verbal informed consent to proceed
with study enrollment; enrolled participants provided writ-
ten informed consent at the ﬁrst clinic appointment. Infor-
mation collected during the enrollment process included:
(i) contact information,
(ii) demographic information (e.g., ethnicity, marital
status, education, and employment status),
(iii) history of medication and substance use,
(iv) medical and obstetrical histories.
Randomization was performed by the Hospital for Sick
Children research support pharmacists. Participants were
randomized to receive either PregVit (containing 1.1mg
of folic acid) or PregVit-Folic5 (containing 5mg of folic
acid). Neither the participants nor the study coordinator
were blinded, as it was not feasible to modify the product
appearance or packaging.
2.2. Study Drugs. PregVit and PregVit-Folic5 are vitamin-
mineral supplements designed for use by planning and
pregnant women. Both PregVit and PregVit-Folic5 are
formulated as two tablets that are to be taken daily: the
pink (am) tablet is taken in the morning and the blue (pm)
tablet in the evening. The pink tablet and blue tablet contain
diﬀerent vitamins and minerals (Table 1); speciﬁcally, iron is
suppliedinthepinktabletandcalciumissuppliedintheblue
tablet to facilitate iron absorption and reduce adverse events
related to iron supplementation.
2.3. Study Procedures. Study visits were conducted in the
Clinical Investigations Unit at the Hospital for Sick Children.
All participants provided witnessed, written informed con-
sent at the beginning of the ﬁrst study visit.
At the ﬁrst study visit, participants provided a fasting
blood sample (5mL) to measure baseline plasma and RBC
folate and plasma vitamin B12. Participants were given an
eight-weeksupplyoftheirassignedmultivitamins,whichwas
renewed at subsequent study visits, and instructed to take
the multivitamins as per the product monograph (i.e., pink
tablet in the morning, blue tablet in the evening). Further
instruction was given to leave missed or skipped doses in
the blister packaging and to return all packaging, including
unused tablets, to the study coordinator. Rates of adherence
were determined based on the number of pills returned.
Participants returned to the hospital at weeks 2, 4, 6, 12, and
30 (±3 days) to provide fasting blood samples (5mL) for
plasma and RBC folate measurements. Plasma vitamin B12
was measured again at week 30.
A validated FFQ [23] was administered during the ﬁrst
and ﬁnal study visits to assess usual dietary folate intake
during the six months prior to study participation and
during the 30 weeks (approximately seven months) of study
participation, respectively.
2.4. Blood Folate Analyses
2.4.1. Blood Sample Preparation. Venous blood samples
were collected in ethylenediaminetetraacetic acid- (EDTA-)
treated blood collection tubes (BD Vacutainer K2 EDTA; BD
Biosciences, Franklin Lakes NJ) after a minimum six-hour
fast. Samples were shielded from light, placed near ice, and
processed within two hours of collection.
To determine the hematocrit (Hct), whole blood was
drawn into 75mm heparinized capillary tubes (Allied Corp.,
Fisher Scientiﬁc; Pittsburgh PA) and centrifuged for 3
minutes (Hettich Haematokrit; Tuttlingen, Germany). Hct
was reported as the mean of at least two determinations.
Whole blood samples were prepared in triplicate in 2mL
polypropylene microtubes (Sarstedt, Inc., Montr´ eal, QC).
Aliquots (100μL) of EDTA-anticoagulated whole blood were
diluted 10-fold in 1% (wt:vol) ascorbic acid (A7631; Sigma-
Aldrich Canada Ltd.; Oakville, ON) in deionized water.
Samples were vortexed and incubated at 37◦Cf o r3 0m i n u t e s
to allow for lysis of red blood cells and deconjugation of
polyglutamylated folates by plasma GGH.
The remaining whole blood was centrifuged at 1500g
for 20 minutes at 4◦C (Allegra 21R Centrifuge; Beckman
Coulter, Inc., Fullerton, CA) to separate plasma from RBCs.
The plasma layer was removed to a 14mL polypropylene
tube (Falcon; BD Biosciences, Franklin Lakes NJ). Aliquots
(500μL) of plasma were transferred to two 2mL polypropy-
lene microtubes for vitamin B12 analysis. Sodium ascorbate
(134032; Sigma-Aldrich Canada Ltd.; Oakville, ON) was
added to the remaining plasma to a ﬁnal concentration of
1% (wt:vol) to prevent oxidative degradation of folate.
Allsampleswerefrozenimmediatelyafterprocessingand
stored at −80◦C.
2.4.2. Aﬃnity-HPLC Assay for Oxidized Folic Acid. Plasma
concentrations of oxidized folic acid were measured by
the aﬃnity-HPLC method with electrochemical detection
described by Bagley and Selhub [24] and Belz and Nau [25].
The aﬃnity column consisted of immobilized FBP that
was isolated from dried whey powder. To isolate FBP, 50g
of dried whey powder (ADM Nutraceuticals; Decatur, IL)
was suspended in 500mL of water and the pH was adjusted
to pH 9 with 5mol/L sodium hydroxide. The suspension
was refrigerated overnight and then centrifuged at 10000g
for 30 minutes at 4◦C. To prepare the column matrix, the
supernatant fraction was allowed to react with Aﬃ-Prep
10 aﬃnity chromatography support (Bio-Rad Laboratories;4 Obstetrics and Gynecology International
Table 1: Composition of study drugs, PregVit and PregVit-Folic5.
Pink (morning) tablet Blue (evening) tablet
Vitamin A (as beta-carotene) 2700IU Folic acid
Vitamin B1 (thiamin mononitrate) 3mg (PregVit) 1.1mg
Vitamin B2 (riboﬂavin) 3.4mg (PregVit-Folic5) 5mg
Vitamin B3 (niacinamide) 20mg Vitamin B12 (cyanocobalamin) 12μg
Vitamin B5 (pantothenate calcium) 5mg Vitamin D3 (cholecalciferol) 250IU
Vitamin B6 (as pyridoxine) 10mg Calcium (calcium carbonate) 300mg
V i t a m i nE( d L - α-tocopheryl acetate) 30IU
Copper (cupric oxide) 2mg
Iodine (potassium iodine) 0.15mg
Iron (ferrous fumarate) 35mg
Magnesium (magnesium oxide) 50mg
Zinc (zinc oxide) 15mg
Mississauga, ON) overnight at 4◦C. The FBP-Aﬃ-Prep 10
slurry was washed sequentially with 20mmol/L triﬂuo-
roacetic acid, 1mol/L potassium phosphate, and deionized
water. To prepare the column, 1mL of the slurry was
transferred to a glass Pasteur pipette packed with glass wool.
Folaterecoveryfromthepreparedcolumn,determinedusing
[3H]-folic acid (Amersham Biosciences; GE Healthcare;
Piscataway, NJ), was 95 ±2% (n = 10).
To prepare the samples for HPLC analysis, frozen plasma
samples were placed in a water bath set at 100◦Cf o r1 0
minutes to denature plasma proteins. Denatured samples
were loaded on the prepared FBP-Aﬃ-Prep 10 column,
which was washed sequentially with deionized water to
remove nonfolate compounds and then mobile phase (equal
proportionsofA,B,andC;describedinfurtherdetailbelow)
to elute the puriﬁed folates.
Folic acid was quantiﬁed in aﬃnity-puriﬁed samples by
reversed-phase HPLC with electrochemical detection. The
HPLC system consisted of a low-pressure gradient pump
(P580A LPG) ﬁtted with an automated sample injector
(ASI-100 Autosampler) set at 4◦C to minimize sample
degradation, phenyl analytical column (250mm × 4.6mm
internal diameter, 5μm particle size; BetaSil∗ Phenyl HPLC
Column) installed in an oven set at 30◦C (STH 585),
and ED50 electrochemical detector with Ag/AgCl reference
electrode managed by a computer running Chromeleon
software (Version 6.2). The analytical column was purchased
from Keystone Scientiﬁc (Thermo Fisher Scientiﬁc, Inc.,
Waltham, MA). All other parts and software were purchased
from Dionex Corp. (Oakville, CA).
T h em o b i l ep h a s ew a sd e l i v e r e da taﬂ o wr a t eo f
0.75mL/min and maintained at 25% A (112mmol/L potas-
sium phosphate, 240mmol/L phosphoric acid), 7% B (80%
(vol:vol) acetonitrile in HPLC-grade water), and 68% C
(HPLC-grade water) for the ﬁrst 10 minutes. Between 10
and 40 minutes, the concentration of B was raised linearly
to 20%, providing the gradient. The folic acid derivative was
identiﬁed on the basis of retention time and comparison to
the electrochemical response of the peak of the folic acid
standard(F8798;Sigma-AldrichCanadaLtd.;Oakville,ON).
The limit of detection (signal-to-noise ratio = 3) of our
HPLC setup was 100pg of folic acid. Samples for which
measured values were below the limit of quantiﬁcation were
spiked with a known quantity of folic acid standard and
reassayed.
Assay performance was evaluated using the standard
curve that was generated at the beginning of each assay by
injecting the folic acid standard in increasing volumes within
the linear range of the assay. Injector precision and retention
time reproducibility were within the speciﬁed limits (relative
standard deviation ≤ 1%).
2.4.3. Microbiological Assay for Total Folate. Plasma and
w h o l eb l o o dt o t a lf o l a t ec o n c e n t r a t i o n sw e r em e a s u r e du s i n g
the microtitre plate method described by Molloy and Scott
[26],withmodiﬁcation,usingthetestorganismLactobacillus
rhamnosus (ATCC 7469; American Type Culture Collection,
Manassas, VA), which was reconstituted (thawed) daily from
a cryopreserved stock.
To prepare the assay medium, 5.7g of dehydrated assay
medium (Difco Folic Acid Casei Medium; BD Biosciences,
FranklinLakes,NJ)wasreconstitutedin100mLofdeionized
water. Ascorbic acid was added to a ﬁnal concentration
of 0.05% (wt:vol) and the mixture was heated. When the
mixture was hot, but not boiling, 30μL of Tween 80 (P8074;
Sigma-Aldrich Canada Ltd.; Oakville, ON) was added and
the mixture was brought to the boil for 2 to 3 minutes. After
cooling slightly, 0.075mg of ascorbic acid was added. The
medium was shielded from light and held in an incubator
at 37◦C while the standards and test samples were prepared
and deposited. When ready, thawed L. rhamnosussuspension
(20μL) was added to 50mL of assay medium.
Frozen plasma and whole blood samples were thawed
at room temperature, shielded from light. Thawed samples
were diluted 80-fold in 1% (wt:vol) sodium ascorbate in
deionized water. Aliquots of 20, 40, and 60μLw e r ed e p o s i t e d
in triplicate. 1% sodium ascorbate was added to a volume of
100μL followed by 200μL of prepared assay medium.Obstetrics and Gynecology International 5
Microtitre plates were covered with aluminum sealing
tape (Corning; Sigma-Aldrich Canada Ltd.; Oakville, ON)
and incubated at 37◦C for 42 hours (Revco Ultima; Thermo
Fisher Scientiﬁc, Inc., Waltham, MA). After 42 hours, the
plates were inverted and agitated to resuspend the cells, and
the sealing tape was removed. The optical density at 590nm
was determined using a 96-well microtiter plate reader
(Opsys MR; DYNEX Technologies; Chantilly, VA) linked to a
computer running the supplied software for data collection
and analysis (Revelation Quicklink; DYNEX Technologies;
Chantilly, VA). Folate concentrations were determined based
on the standard curve that was generated for each plate.
The standard curve was based on a folic acid standard
(0.5ng/mL) that was prepared daily from a frozen stock and
deposited in triplicate in aliquots of 0 to 100μL( 0t o5 0p go f
folic acid).
All samples for a given subject were analyzed as a set to
reduce intraperson variability. Measurements were discarded
if the coeﬃcient of variation for the triplicate exceeded 5%
or if the measurements did not fall in linear range of the
standard curve (7–21pg); if no usable values remained for
one or more weeks from a given subject, all samples from
thatsubjectwerereassayed,adjustingthedilutionsasneeded.
Otherwise, reported values (in picograms) were plotted
against the volume of the initial aliquot (i.e., 20, 40, and
60μL); the slope of the line of best ﬁt gave the folate
concentration in the reaction well, which was multiplied by
the dilution factor to determine the folate concentration in
theplasmaorwholeblood sample.RBCfolatewascalculated
according to the following equation:
RBC folate
=
whole blood folate −

(1 −Hct) × plasma folate

Hct
.
(1)
Assay performance (accuracy and interassay variability)
was assessed using a certiﬁed whole blood folate standard
(95/528; National Institute for Biological Standards and
Control, Hertfordshire, UK) that was analyzed in triplicate
at two diﬀerent dilutions on each plate. Reported values were
checked against a quality control chart prepared in advance
from twenty consecutive assays in which the standard was
similarly analyzed. The acceptable limits were deﬁned as ±1
standard deviation from the mean of these twenty determi-
nations. Our analyses yielded an overall interassay coeﬃcient
of variation of 3.4% and a measured concentration of 30.6 ±
1.0nmol/L (stated value: 29.5nmol/L; [27]).
2.5. Dietary Folate Analyses. The Block Folic Acid/Dietary
Folate Equivalents (DFE) Screener (NutritionQuest; Berke-
ley CA) was administered to assess dietary folate intake.
The DFE Screener is an abbreviated folate-targeted food
and supplement screening tool that was developed based
on dietary data from NHANES 1999-2000 and designed to
assess usual and customary folate intake in women [27–29].
It includes 19 food groups and two supplement questions.
Questionnaires were processed and analyzed by Nutri-
tionQuest (Berkeley, CA). The results were reported as:
(a) naturally occurring food folates (μg),
(b) folic acid from folic acid-fortiﬁed foods (μg),
(c) total food folate, μg (sum of (a) and (b)),
(d) total food folate, μgD F E( μgD F E= (a) + (b) × 1.7).
2.6. Statistical Analyses. Data were tested for normality using
the Shapiro-Wilk test, and parametric or nonparametric
tests were performed as appropriate. All statistical analyses
were performed using SAS for Windows (Version 9.1; SAS
Institute, Inc.; Cary NC), except for the Friedman test due
to the lack of posthoc analysis options in SAS. Results were
considered statistically signiﬁcant at a P value of ≤0.05.
Subject characteristics are presented as mean ± standard
deviation or median (range). Between-group comparisons
were performed using Student’s t-test, Wilcoxon-Mann-
Whitney test, or Fisher’s exact test. Dietary folic acid intake
and dietary total folate intake were compared between
groupsandovertimebyusingtheMIXEDprocedure(PROC
MIXED) in SAS for Windows. The MIXED procedure ﬁts
mixed linear models to data and estimates and tests the
signiﬁcance of between- and within-subject eﬀects.
The relationships between plasma unmetabolized folic
acid and (i) dietary folic acid intake, (ii) dietary total
folate intake, (iii) total plasma folate concentration, and (iv)
total RBC folate concentration were evaluated by calculating
Kendall’s tau-b rank correlation coeﬃcient, which measures
association based on concordance and discordance between
paired observations. Kendall’s tau-b was seen as preferable to
Spearman’srhoduetothenumberoftiedranks(i.e.,samples
that were below the LOD).
Frequency data, including the proportion of women with
detectable concentrations of unmetabolized folic acid, were
analyzed by Fisher’s exact test for between-group compar-
isons or Cochran’s Q test for within-group comparisons (i.e.,
change over time). A signiﬁcant Q statistic was investigated
further by planned posthoc pair-wise comparisons using
McNemar’s test with Bonferroni correction for multiple
testing to maintain a procedure-wise type I error rate of 0.05.
As unmetabolized folic acid concentrations were not
normally distributed and it was not feasible to transform
the data to ﬁt a normal distribution, the eﬀect of folic acid
supplementation on plasma folic acid was analyzed using
the Friedman test in WINKS SDA 6.0 (TexaSoft; Cedar Hill
TX). A signiﬁcant χ2 statistic was investigated further by
nonparametric posthoc pair-wise comparisons with Tukey
adjustment for multiple testing.
3. Results
3.1. Study Population. Between March 2007 and February
2008, sixty-three healthy, nonpregnant women of repro-
ductive age were approached for participation in this
study (Figure 2). Twenty-three women were excluded, either
because they did not meet the inclusion criteria (n = 21)
or because they did not wish to participate (n = 2); thus6 Obstetrics and Gynecology International
Assessed for eligibility
(n = 63)
Excluded (n = 23)
Did not meet inclusion criteria (n = 21)
Refused to participate (n = 2)
Randomized
(n = 40)
Allocated to 1.1 mg group (n = 20)
Received allocated intervention (n = 20) Allocation
Allocated to 5 mg group (n = 20)
Received allocated intervention (n = 20)
Discontinued intervention (n = 1)
Anxiety with blood work (n = 1) Followup
Discontinued intervention (n = 1)
Could not commit (n = 1)
Analyzed (n = 19) Analysis Analyzed (n = 19)
Figure 2: Consolidated Standards of Reporting Trials (CONSORT) patient ﬂow diagram.
40 women were enrolled. Twenty women were randomized
to take the multivitamin containing 1.1mg of folic acid;
twenty women were randomized to take the multivitamin
containing 5mg of folic acid. One woman from each group
withdrew from the study after the baseline measurement due
toanxietywiththebloodwork(n = 1)orinabilitytocommit
to the study timeline (n = 1). Nineteen women in each
groupcompletedthestudyprotocolandwereincludedinthe
analyses.
There were no signiﬁcant diﬀerences between the two
groups of women in the collected patient characteristics
(Table 2).Exceptforonewomanwhowasastudentpursuing
postsecondary education, all of the women had earned a
postsecondary degree (either college or university). The
majority of the women were employed—either part time
or full time. As per the inclusion criteria, all participants
were healthy and were not taking any medications on a
chronic basis. In the 1.1mg folic acid group, one woman
used acetaminophen or ibuprofen for infrequent migraine
headaches and one used minocycline for acne on an “as
needed” basis. In the 5mg folic acid group, two women
reported occasional use of salbutamol for asthma and
one received desensitization shots for seasonal allergies.
Occasional (social) alcohol consumption was reported by
the majority of the women and did not diﬀer signiﬁcantly
between the two groups. One woman in the 5mg group
reported light cigarette smoking.
3.2. Relationship between Plasma Folic Acid and Other
Indicators of Folate Status. The relationships between plasma
concentration of unmetabolized folic acid and dietary folate
intakes and between plasma folic acid and total blood folate
concentrations were evaluated by calculating Kendall’s tau-
b rank correlation coeﬃcient. Correlation coeﬃcients were
calculated within each group and for pooled data from
both groups, as these analyses were performed on baseline
data (i.e., samples collected before supplementation was
started).
Plasma folic acid was not found to be signiﬁcantly
correlated with dietary folic acid or dietary total folate
(Figure 3) when analyzed by group or in pooled data. A
signiﬁcantnegativecorrelationwasobservedbetweenplasma
folic acid and RBC total folate in the 1.1mg group (Kendall’s
τb =− 0.36, P = 0.04), but not in the 5mg group or
in pooled data. After Bonferroni correction for multiple
testing, however, the correlation did not retain statistical
signiﬁcance (critical P value = 0.05 ÷ 12 = 0.004). No other
signiﬁcant correlations were observed between plasma folic
acid and plasma total folate (Figure 4) or RBC total folate
(Figure 5).
Subjects were then grouped according to whether or
not unmetabolized folic acid was detectable at baseline and
compared on the same dietary and biochemical variables
(Table 3). Neither dietary folic intake nor dietary total
folate intake was signiﬁcantly higher among individuals withObstetrics and Gynecology International 7
Table 2: Patient characteristics.
PregVit (1.1mg folic acid) (n = 19) PregVit-Folic5 (5mg folic acid) (n = 19) Pa
Age (years) 33.4 ±5.53 5 .1 ±7.00 . 4 0
Weight (kg) 54.5 (45.5–90.9) 61.8 (50.08–6.36)b 0.98
Gravidityc 0 (0–4) 1 (0–6) 0.86
Ethnicity 0.29
Caucasian 14 14
Hispanic 1 0
South Asian 3 1
Oriental Asian 1 4
Education 0.78
High school 0 1
College 6 4
University 12 12
Postgraduate 1 2
Employment 0.73
Student 2 4
Part time 2 1
Full time 14 14
Homemaker 1 0
Substance use
Alcohol 11 15 0.29
Cigarettes 0 1 >0.99
aP value, as determined by Student’s t-test, Wilcoxon-Mann-Whitney test, or Fisher’s exact test.
bData was missing for one patient (i.e., n = 18).
cThe proportion of women who had been pregnant before was not signiﬁcantly diﬀerent between the two groups (9/19 versus 10/19; Fisher’s exact test, P>
0.99).
Table 3: Baseline dietary and biochemical data for participants with detectable or undetectable (i.e., below the LOD) plasma concentrations
of unmetabolized folic acid.
Undetectable (n = 13) Detectable (n = 25) Pa
Plasma folic acid (nmol/L) — 8.8 (0.27–41.9) —
Dietary folic acid (μg/day) 188.5 (56.8–380.0) 191.8 (70.6–395.8) >0.99
Dietary total folate (μg DFE/day) 477.5 (181.9–849.2) 450.4 (231.9–979.4) 0.52
Plasma total folate (nmol/L) 48.7 (30.3–87.7) 43.7 (27.4–84.8) 0.27
RBC folate (nmol/L) 969.2 (761.0–1777.5) 1018.61 (710.3–2355.1) 0.88
aP value, as determined by Wilcoxon-Mann-Whitney test (due to unequal sample sizes).
detectable folic acid compared to those with undetectable
levels; similarly, neither plasma nor RBC total folate concen-
trations were signiﬁcantly diﬀerent between the two groups.
3.3. Eﬀect of Folic Acid Supplementation on Plasma
Concentrations of Unmetabolized Folic Acid
3.3.1. Adherence to Multivitamin Supplementation. Adverse
events were reported by fourteen women (37%) over the
courseof30weeksofmultivitaminsupplementation,includ-
ing nausea (n = 5), constipation (n = 3), abdominal
discomfort (n = 3), diarrhea (n = 1), diﬃculty swallowing
(n = 1), and heartburn (n = 1). All adverse events were mild
in nature, however, and none of the women discontinued
supplementation or withdrew from the study as a result of
the event. Moreover, there was no signiﬁcant diﬀerence in
adverse events between the two groups.
The median rate of adherence was 88.8% (29.8–100%)
in the 1.1mg group and 89.8% (range 37.9–99.5%) in the
5mg group (Figure 6). The diﬀerence was not signiﬁcant
(z =− 0.37; P = 0.71).
3.3.2. Proportion of Plasma Samples with Detectable
Folic Acid. The limit of detection (LOD) of our aﬃnity
chromatography-HPLC assay was 100pg (0.18nmol/L).
Before supplementation, the proportion of women with a
plasma concentration of unmetabolized folic acid that was
above the LOD was 0.63 (95% CI, 0.39–0.83) in the 1.1mg
group and 0.68 (95% CI, 0.44–0.86) in the 5mg group
(Figure 7). There was a signiﬁcant change in the proportion
of women with detectable concentrations of folic acid over
time in both the 1.1mg group (Cochran’s Q = 33.89; df = 3;
P<0.001) and the 5mg group (Cochran’s Q = 33.69;
df = 3; P<0.001). Posthoc comparisons to baseline were8 Obstetrics and Gynecology International
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Figure 3: Relationship between plasma folic acid and dietary folic
acid intake. 1.1mg group (triangles): Kendall’s τb = 0.12, P = 0.47.
5mg group (squares): Kendall’s τb =− 0.18, P = 0.29. Pooled:
Kendall’s τb =− 0.026, P = 0.83.
statistically signiﬁcant for week 6 and week 12 (P<0.017)
but not week 30 in both groups (1.1mg: P = 0.32, 5mg:
P = 0.32; Table 4). Comparing the proportions at each time
point, there were no signiﬁcant diﬀerences between the
1.1mg and 5mg groups (Fisher’s exact test; P>0.99).
In the 1.1mg group, of the seven women who had
undetectable plasma concentrations of folic acid at baseline,
all had undetectable concentrations of folic acid at week 30;
of the 12 women who had detectable folic acid at baseline,
eleven had detectable concentrations of folic acid at week 30
(kappa = 0.89; 95% CI, 0.68–1.00). A slightly lower level of
agreement was observed in the 5mg group of the six women
who had undetectable plasma concentrations of folic acid at
baseline, ﬁve had undetectable concentrations at week 30; of
the thirteen women who had detectable folic acid at baseline,
ten had detectable concentrations at week 30 (kappa = 0.55;
95% CI, 0.18–0.93).
3.3.3. Plasma Concentrations of Unmetabolized Folic Acid.
The distribution of plasma concentrations of unmetabolized
folic acid was not normal, nor was it feasible to transform
the data to ﬁt a normal distribution due to the proportion of
samples that were below the LOD at baseline and at week 30.
The data were, therefore, analyzed using the Friedman test, a
nonparametric equivalent to the repeated measures analysis
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100 80 60 40 20 0
P
l
a
s
m
a
 
f
o
l
i
c
 
a
c
i
d
 
(
n
m
o
l
/
L
)
50
40
30
20
10
0
5 mg
1.1 mg
Group
Figure 4: Relationship between plasma folic acid and plasma total
folate. 1.1mg group (triangles): Kendall’s τb =− 0.26, P = 0.14.
5mggroup(squares):Kendall’sτb =− 0.073,P = 0.67.Pooleddata:
Kendall’s τb =− 0.16, P = 0.18.
Table 4: Within-group comparisons of the proportion of plasma
samples with detectable concentrations of unmetabolized folic acid.
McNemar’s S df Pa
1.1mg group
Week 0 versus week 6 7.00 1 0.008
Week 0 versus week 12 7.00 1 0.008
Week 0 versus week 30 1.00 1 0.32
5mggroup
Week 0 versus week 6 6.00 1 0.014
Week 0 versus week 12 6.00 1 0.014
Week 0 versus week 30 1.00 1 0.32
aCritical P value = 0.0167 after Bonferroni correction for 3 pair-wise
comparisons within each group (0.05 ÷ 3 = 0.0167).
of variance. The data were ﬁrst analyzed by group (Figures 8
and 9).
At baseline, the median plasma concentration of
unmetabolized folic acid was 4.8nmol/L (undetectable to
41.9nmol/L) in the 1.1mg group compared to 3.7nmol/L
(undetectable to 22.7nmol/L) in the 5mg group (z =
0.06; P = 0.95). When analyzed by group, the change in
plasma folic acid over 30 weeks of supplementation was not
signiﬁcant in the 1.1mg group (χ2 = 4.71; df = 3; P = 0.20)
or the 5mg group (χ2 = 6.3; df = 3; P = 0.10).
When pooled data from both groups were analyzed, the
change in plasma folic acid was found to be signiﬁcantObstetrics and Gynecology International 9
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Figure 5: Relationship between plasma folic acid and RBC total
folate. 1.1mg group (triangles): Kendall’s τb =− 0.36, P = 0.04.
5mg group (squares): Kendall’s τb = 0.15, P = 0.39. Pooled data:
Kendall’s τb =− 0.068, P = 0.56.
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Figure 6: Rates of adherence to multivitamin supplementation.
(χ2 = 10.39; df = 3; P = 0.019). Posthoc nonparamet-
ric multiple comparisons revealed a signiﬁcant diﬀerence
between plasma concentrations of unmetabolized folic acid
at week 12 and week 30 (Q = 4.04; P<0.05).
Comparing plasma folic acid between the two groups
at each time point, there were no signiﬁcant diﬀerences
(Table 5)
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Figure 7: Proportion of plasma samples with detectable concen-
trations of unmetabolized folic acid. Detection rates at week 6 and
week 12 were signiﬁcantly higher compared to baseline (week 0) in
both the 1.1mg (#) and 5mg (§) groups.
3.3.4. Estimated Dietary Folate Intake. The Block DFE
Screener was administered twice during the study—at the
baseline study visit to estimate usual folate intake in the
six months preceding study participation and at the ﬁnal
study visit to estimate usual folate intake over the course of
the study. Diﬀerences between groups and over time were
evaluated by mixed-model analysis of variance. There was
no signiﬁcant diﬀerence between the two groups at baseline
or week 30 in dietary folic acid or dietary total folate intake;
similarly, there was no signiﬁcant change in dietary folic acid
or dietary total folate intake from baseline to week 30 (Tables
6 and 7). Thus observed changes in unmetabolized folic acid
were most likely due to the intervention, as there was no
signiﬁcant change in dietary intake.
4. Discussion
The women participating in this study were recruited
primarily through advertisements posted in The Hospital
for Sick Children and through word-of-mouth. Consistent
with other studies conducted through the Motherisk pro-
gram, the women participating in this study tended to be
highly educated and of higher socioeconomic status. All
of the women were either enrolled in or had completed
postsecondary education; the majority was employed full
time. As several studies have shown socioeconomic status,
which encompasses education, employment, and income,
to be a predictor of folate intake and adequacy [28–31],10 Obstetrics and Gynecology International
Table 5: Between-group comparisons of plasma concentrations of unmetabolized folic acid.
Plasma folic acid (nmol/L)
1.1mg 5mg zP a
Week 0 4.76 (ND–41.90) 3.67 (ND–22.71) 0.06 0.95
Week 6 7.23 (1.79–81.92) 6.05 (0.18–28.98) 1.26 0.21
Week 12 8.34 (2.42–86.43) 8.02 (0.97–24.31) −0.11 0.91
Week 30 3.13 (ND–29.66) 4.35 (ND–16.45) 0.06 0.95
aP value, as determined by Wilcoxon-Mann-Whitney test.
Table 6: Estimated dietary folic acid intake (μg/day).
Week 0 Week 30 P (week 0 versus week 30)
1.1mg 221.5 ±93.9 218.9 ±93.4 >0.99
5mg 194.3 ±82.8 230.1 ±116.30 . 2 2
P (1.1mg versus 5mg) 0.78 0.99
∗There was no signiﬁcant eﬀect of time (F(1, 36) = 1.65; P = 0.21), group (F(1, 36) = 0.08; P = 0.78), or time-group interaction (F(1, 36) = 2.19; P = 0.15).
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Figure 8: Plasma concentrations of unmetabolized folic acid
among women who supplemented with 1.1mg of folic acid (grey
boxes) compared to 5mg of folic acid (cross-hatched boxes). When
analyzed by group, the change in plasma folic acid concentrations
was not signiﬁcant in either the 1.1mg (P = 0.20) or 5mg (P =
0.10) group.
it was not surprising that most of the women (84%) had
usual dietary folate intakes that met or exceeded the EAR
for folate (320μg/day DFE) from diet alone. Approximately
three-quarters of the women met or exceeded the RDA
of 400μg/day DFE; none of the women exceeded the
UL for folic acid. Estimated dietary total folate intakes
(i.e., including natural food folates and folic acid-fortiﬁed
foods) in our study group were similar to those reported
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Figure 9: Plasma concentrations of unmetabolized folic acid
among women who supplemented with either 1.1mg or 5mg of
folic acid (all participants combined). When pooled data from both
groups were analyzed, there was a signiﬁcant change in plasma folic
acidconcentrations(P = 0.019).(∗)Therewasasigniﬁcantdecline
from week 12 to week 30 (P<0.05).
previouslyamongCanadianwomenofreproductiveage[32–
34]. Dietary folate intakes remained relatively stable over the
course of the study.
None of the participants were found to be folate
deﬁcient (serum/plasma folate < 7nmol/L or RBC folate
< 360nmol/L). Consistent with a recent report on folate
status of women of reproductive age in Ontario, about two-
thirds of the women had RBC folate concentrations that are
associated with a very low risk for NTDs (>906nmol/L);
one-third of the women, therefore, would be at higher-than-
baseline risk for NTDs, if they were to become pregnant.Obstetrics and Gynecology International 11
Table 7: Estimated dietary total folate intake (μgD F E / d a y ) .
Week 0 Week 30 P (week 0 versus week 30)
1.1mg 525.6 ± 192.2 510.5 ±191.50 . 9 7
5mg 491.1 ± 185.6 541.2 ±248.80 . 6 4
P (1.1mg versus 5mg) 0.94 0.97
∗There was no signiﬁcant eﬀect of time (F(1, 36) = 0.43; P = 0.52), group (F(1, 36) = 0.00; P = 0.98), or time-group interaction (F(1, 36) = 1.47; P = 0.23).
4.1. Baseline Concentrations of Unmetabolized Folic Acid. To
date, there have been two large population-based studies
that examined circulating folic acid concentrations in a
country with mandatory folic acid fortiﬁcation. One study
measured unmetabolized folic acid concentrations in plasma
samples collected during the sixth examination cycle of
the Framingham Oﬀspring Cohort study, which took place
between January 1995 and August 1998 [35]; the second
study measured folic acid in surplus serum samples collected
from NHANES 2001-2002 participants’ ≥60 years of age
[36].
Theprevalenceofdetectablelevelsofunmetabolizedfolic
acid in our population at baseline was similar to the preva-
lence in non-B vitamin users in the Framingham Oﬀspring
Cohort examined after fortiﬁcation (67%). In contrast, the
median folic acid concentration in our study population was
severaltimeshigher(3.76nmol/Lcomparedto0.50nmol/L).
In the NHANES data set, both the detection rate (38%) and
the mean folic acid concentration (1.7nmol/L; the median
was not reported) were lower compared to our population.
The underlying reasons for the apparent discrepancies
between detection rates and plasma concentrations are
unclear. We used an aﬃnity-HPLC method with electro-
chemical detection based on the method described by Bagley
and Selhub [24], as did the Framingham Oﬀspring Cohort
and NHANES studies. The reported detection limits were
similar (0.18nmol/L). However, as reviewed by Bailey and
colleagues [36], available studies of unmetabolized folic
acid do not demonstrate a relationship between detection
rates and LODs, suggesting that the observed discrepancies
are more likely due to real diﬀerences between the study
populations rather than methodological issues. Both the
Framingham Oﬀspring Cohort and NHANES studies exam-
inedanolderpopulationconsistingofbothmenandwomen,
whereas our population consisted of women of reproduc-
tive age. The NHANES population is heterogeneous and
nationally representative whereas the Framingham Oﬀspring
Cohort and our population are more homogenous and self-
selected.
Kalmbach and colleagues identiﬁed four predictors of
“high” folic acid concentrations: dietary folic acid intake,
dietary total folate intake, use of B-vitamin supplements,
and plasma total folate [35]. We excluded women who
reported use of folic acid-containing supplements in the six
months preceding study participation and the remaining
three measures were not substantially higher in our study
population compared to those reported for non-B vitamin
users in the Framingham Oﬀspring Cohort. Interestingly,
these three measures also did not diﬀer between participants
with detectable and undetectable folic acid within our
population,althoughthepowerofthiscomparisonmayhave
been limited by the smaller number of women who had
undetectable folic acid (n = 13). Another study described
a possible “threshold” eﬀect for serum total folate such that
the proportion of serum folate as folic acid in samples above
50nmol/L was found to be signiﬁcantly higher compared
to those below 50nmol/L [37]. Approximately one-third of
the women in this study had a baseline plasma total folate
concentration that was greater than 50nmol/L; however,
these thirteen women accounted for almost half of the
plasma samples that did not have detectable levels of folic
acid. Therefore the higher baseline folic acid concentrations
in our population compared to the Framingham Oﬀspring
Cohort are not well explained by these factors.
4.2. Relationship between Plasma Folic Acid and Other
Measures of Folate Status. The majority of studies describing
adverseeﬀectsoffolicacidand/orfolatehaveevaluatedexpo-
sures in terms of high folic acid intakes or high plasma or
serumfolateconcentrations.Circulatingunmetabolizedfolic
acid has only recently gained the attention of researchers,
as prior to the development of chromatographic methods
for measuring folate in biological samples, available methods
(e.g., microbiological assays, folate-binding assays) did not
distinguish between folic acid and reduced folates. With the
advent of these chromatographic methods, studies have been
able to show that dietary folate intakes and blood folate
concentrations are predictive of circulating folic acid. To
date, however, these relationships have not been studied in
a Canadian population.
The majority of the women (79%) did not have usual
dietary folic acid intakes that exceeded the threshold dose for
the appearance of unmetabolized folic acid in plasma; none
consumed more than 400μg/day, which has been shown to
produce a sustained appearance of folic acid in plasma [38].
That folic acid was detectable in the majority of women in
spite of low estimated folic acid intakes suggests that either
(a) threshold doses are in fact lower than previously reported
or (b) estimated folic acid intakes provided by the Block DFE
Screener were not accurate.
The activity of DHFR, which is the rate-limiting step in
the conversion of folic acid to 5-CH3-H4PteGlu, is highly
variable. In a study using fresh human liver tissue, DHFR12 Obstetrics and Gynecology International
activity was found to vary approximately ﬁvefold among
samples [39]. Presumably, individuals with lower levels of
DHFR activity would have lower thresholds and individuals
with higher levels of DHFR activity could consume and
metabolize larger doses of folic acid. Such variation in the
metabolism of folic acid could explain why, contrary to
our hypothesis, we did not observe a signiﬁcant correlation
betweenplasmafolicacidanddietaryfolicacidortotalfolate
intake.
In the present study, dietary folic acid and dietary total
folate intakes were estimated using the Block DFE Screener,
a validated, folate-targeted, semiquantitative FFQ designed
to measure usual and customary intake of dietary and
supplemental folate. It was designed as an instrument that
would rank subjects well according to folate intake and
includes the 19 food groups that contributed to 60% of total
folate intake in the United States in NHANES 1999-2000
[40]. However, dietary patterns of Canadians and Americans
may be quite diﬀerent and the quality of food composition
tables has been called into question [41], which could reduce
the validity of this questionnaire in our population and
attenuate the correlation with plasma folic acid.
A recent study of pregnant and postpartum women in
Canada found that, similar to NHANES 1999-2000 data,
grainproductswerethegreatestcontributorstodietaryfolate
intake, followed by fruits and vegetables [33]. These groups
are well represented in the Block DFE Screener; however,
there are items included in the questionnaire that are not
major contributors to Canadian intakes, including meal
replacement drinks and bars, hot cereals, tortillas, and beer.
Conversely, there are major contributors to dietary folate
intake among Canadian women that are not represented in
the Block DFE Screener, including dairy products and fast
foods. The omission of these food groups could result in
inaccurate estimates of folic acid intake for women who
consume them.
4.2.1. Relationship between Plasma Folic Acid and Blood
Total Folate. Therelationshipbetweenplasmaconcentration
of unmetabolized folic acid and plasma total folate has
been evaluated in several studies. Sweeney and colleagues
measured plasma folic acid and plasma total folate in
fasting plasma samples obtained from women undergoing
elective Caesarean section and in nonfasting plasma samples
obtained from a random sampling of individuals attending a
blood donor clinic [42]. In both populations, plasma folic
acid and plasma total folate were signiﬁcantly correlated,
although the strength of the correlation was stronger in
fasting samples (n = 20; r2 = 0.300) compared to nonfasting
samples (n = 50; r2 = 0.110).
In general, studies that found an association between
plasma folic acid and plasma or serum total folate included
both supplement users and nonusers. As a result, although
dietary folic acid intakes were comparable to intakes in
our population, mean or median total folic acid intakes
(i.e., diet and supplements combined) were higher and
the ranges of intakes were larger. The restricted range of
dietary folic acid intakes in our population might explain
the absence of correlation between plasma folic acid and
plasma total folate. Because the median plasma total folate
concentration in our study was comparable to, if not higher
than, mean or median concentrations in previous studies,
this further suggests that women in our study were achieving
higher plasma folate concentrations as a result of higher
intakes of naturally occurring food folates, and not folic
acid.
4.3. Eﬀect of Folic AcidSupplementation on CirculatingUnme-
tabolized Folic Acid. Current guidelines advise all women
who could become pregnant to consume a daily multivita-
min containing 0.4mg to 1mg of folic acid [43–45]. Women
who are at higher risk for having a baby with a NTD are
advised to consume a daily multivitamin containing 4 to
5mg of folic acid, beginning at least three months before
conception. Some authorities also recommend the high-dose
strategy for women who have a history of poor medication
adherence in addition to lifestyle issues that may increase
their risk for NTDs [43].
Until recently, however, there was limited data on the
pharmacokinetics of the higher dose of folic acid. Nguyen
and colleagues were the ﬁrst to formally investigate the
single-dose and steady-state pharmacokinetics of the 5mg
dose of folic acid in women of reproductive age [22, 46].
As the high-dose strategy provides more than ten-times
the dosage that appears to saturate both hepatic metabolic
capacity and plasma clearance mechanisms, we decided to
expand on these ﬁndings by examining the eﬀect of daily
supplementation with 5mg compared to 1.1mg of folic
acid on fasting plasma concentrations of unmetabolized
folic acid. To the best of our knowledge, this was the ﬁrst
interventional study to evaluate the eﬀects of long-term
folic acid supplementation on plasma concentrations of
unmetabolized folic acid among women of reproductive age
who are also exposed to folic acid fortiﬁcation.
4.3.1. Supplementation Increases Plasma Concentrations of
Unmetabolized Folic Acid. We observed a signiﬁcant increase
in the proportion of women with detectable levels of
unmetabolized folic acid over the ﬁrst 12 weeks of sup-
plementation; concentrations of unmetabolized folic acid
also appeared to increase, however, although the overall
eﬀect of supplementation was signiﬁcant, the diﬀerences
between baseline and week 6 or week 12 were not statistically
signiﬁcant. This suggests that, although there is an eﬀect of
supplementation, it is small relative to the natural variation
in circulating folic acid concentrations.
There is limited information on the eﬀect of folic acid
supplementation on plasma concentrations of unmetabo-
lized folic acid. Bailey and colleagues have presented, in
abstract form, preliminary data from a series of small trials
evaluating the eﬀects of 10 to 12 weeks of daily supplemen-
tation with 0.4 to 5mg of folic acid in adults in the United
Statesafterfortiﬁcation[47–49].Thesestudiesincludedboth
men and women of varying ages and ethnicities. Plasma
concentrations of unmetabolized folic acid at baseline were,
on average, 0.5 to 0.7nmol/L. At the lowest dose testedObstetrics and Gynecology International 13
(i.e., 0.4mg/day), plasma folic acid increased approximately
twofold over 12 weeks of supplementation. With higher
doses (i.e., 1mg/day, 2.5mg/day, or 5mg/day), plasma folic
acid concentrations increased approximately threefold.
Similar to Bailey and colleagues’ ﬁndings, we also found
thatthemedianplasmaconcentrationofunmetabolizedfolic
acid doubled (approximately) over the ﬁrst 12 weeks of
supplementation; this was true in spite of baseline values
in our population that were, on average, ﬁve-times higher.
The discrepancy in baseline values is likely due in part
to their exclusion of not only individuals who consumed
folic acid supplements in the three months preceding their
participation in the study, but also those who reported
“signiﬁcant” consumption of folic acid from dietary sources
(e.g.,fortiﬁedbreakfastcereals,energybars,etc.)(J.E.Ayling,
personal communication). There are likely other diﬀerences
between the study populations with respect to characteristics
such as age, sex, and ethnicity—some of which may be
associated with diﬀerences in folic acid metabolism.
It has been suggested that individuals who have
detectable levels of unmetabolized folic acid may represent
a subpopulation that has altered folic acid metabolism and
responds diﬀerently to ingested folic acid [36]. In our study,
all of the women had detectable folic acid at some time over
the course of supplementation; however, it is interesting to
notethatalmostallofthewomenwhohadundetectablefolic
acid at baseline also had undetectable levels at week 30 and
almostallofthewomenwhohaddetectablefolicacidatweek
30 also had detectable levels at week 30. It is also interesting
to note that, comparing the “detectable” and “undetectable”
groups, there was no signiﬁcant diﬀerence in dietary folic
acid or total folate intake, suggesting that the women who
had detectable folic acid at baseline and throughout the
study may represent a “sensitive” group in our population.
It would have been interesting to investigate the eﬀects of
folicacidsupplementationamongthesewomencomparedto
thewomenwhohaddetectablelevelsonlyduringtheinterim
study visits, however, our limited sample size precluded such
analyses.
If such subpopulations do exist and were more highly
represented in our study compared to Bailey and colleagues’
studies, this might also explain the diﬀerences in baseline
concentrations of unmetabolized folic acid and response to
supplementation.
4.3.2. Plasma Concentrations of Unmetabolized Folic Acid
Do Not Remain Elevated. An unexpected observation was
a signiﬁcant decline in concentrations of unmetabolized
folic acid between week 12 and week 30, despite ongoing
supplementation and sustained total folate concentrations.
In fact, plasma concentrations of unmetabolized folic acid at
week 30 were not signiﬁcantly diﬀerent from concentrations
at baseline. Preliminary data from a study that examined
folic acid concentrations before and after six months of folic
acid supplementation among women of reproductive age
observed only minimal changes in folic acid concentrations
with doses up to 4mg/day [37], which is similar to what
we observed in our population. Unfortunately, data were
not available (or not collected) at smaller intervals over the
course of supplementation, thus it is not known whether
unmetabolized folic acid concentrations were signiﬁcantly
higher during the interim, as they were in ours (compared
to week 30).
We ﬁrst considered the possibility that adherence
decreased over the latter half of the study. In a recent study
of prenatal multivitamin supplementation in a cohort of
Motherisk callers who had either discontinued a previous
multivitamin or had yet to start multivitamin supple-
mentation in pregnancy, the most common reasons for
discontinuing or not starting supplementation were nausea
and vomiting of pregnancy (NVP), diﬃculty with taking
multivitamins, and adverse gastrointestinal events. Women
in the present study, however, did not experience NVP
(as they were not pregnant) and although approximately
one-third of the women reported adverse events, all were
mild in nature and did not result in discontinuation of
the intervention or withdrawal from the study. In fact, the
medianrateofadherenceapproached90%ineachgroup.We
did not obtain week-by-week or month-by-month records
of pill intake, thus we cannot exclude the possibility that
adherence was higher in the initial weeks of the study
before falling oﬀ towards the end; however, no decrease was
observed in plasma or RBC total folate concentration. This
suggests that pill intake occurred at relatively consistent rate
over the course of the study and that the decrease in plasma
folic acid was not the result of decreased adherence.
One possible mechanism for the observed decline in
plasmaconcentrationsofunmetabolizedfolicacidisupregu-
lationoffolicacidmetabolism[9,50].Kamenandcolleagues
found that, as compared to human liver cells in situ, the
expression and activity of DHFR was 100- to 200-times
higher in human cell lines in vitro and fresh rat liver cells.
I tw a sp o s t u l a t e dt h a te x p o s u r et oh i g hl e v e l so ff o l i ca c i d
in culture medium and laboratory rodent chow upregulated
DHFR activity in cultured cells and in laboratory animals
[51]. Theoretically, a similar process may occur in DHFR at
the intestinal mucosa.
DHFR expression is partly controlled by a translational
autoregulatory mechanism, where binding of DHFR to
its cognate mRNA inhibits translation of the transcript
[23]. Binding of H2PteGlu to the DHFR-mRNA complex
induces a conformational change that releases the mRNA
transcript, resulting in resumption of translation and DHFR
synthesis. As the ﬁrst step in the metabolism of folic acid
to coenzymatic forms is the reduction of folic acid to
H2PteGlu, cells exposed to high levels of folic acid would
likely accumulate high levels of H2PteGlu as well. Thus
f o l i ca c i d ,v i ar e d u c t i o nt oH 2PteGlu, could theoretically
upregulate DHFR expression by translational derepression.
Further studies are needed to determine whether or not
induction of DHFR by folic acid occurs in vivo and, if so,
to what clinical outcome.
4.3.3. Eﬀect of Dose of Folic Acid Supplementation. Con-
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unmetabolized folic acid were not signiﬁcantly higher in the
5mg group compared to the 1.1mg group. This is consistent
withpreliminarydatafromtheseriesofstudiesconductedby
Bailey and colleagues that found no signiﬁcant diﬀerence in
folic acid concentrations achieved over 10 weeks of supple-
mentation with daily doses up to 5mg (compared to 1mg)
[47–49]. Although we cannot exclude the possibility that
individualsconsumingasupplementcontaining5mgoffolic
acid daily will temporarily be exposed to higher amounts
of folic acid immediately after dosing, taken together, these
data suggest saturation of folic acid uptake and/or retention
and the existence of mechanisms that restore and maintain
folate homeostasis following ingestion of pharmacological
doses of folic acid. Nguyen and colleagues’ analysis of plasma
a n dR B Ct o t a lf o l a t ec o n c e n t r a t i o n sa c h i e v e di nt h i st r i a lo f
folic acid supplementation were also suggestive of a limiting
mechanism, as only a twofold diﬀerence in plasma and RBC
total folate concentrations was observed despite a ﬁvefold
diﬀerence in dose [22].
At physiological doses, folic acid is absorbed via carrier-
mediated transport involving the PCFT and RFC [7].
Pharmacological doses, however, saturate carrier-mediated
transport systems and are likely absorbed primarily via
passive diﬀusion [4]. As passive diﬀusion is a slower and
less eﬃcient means of absorption, this may explain the
apparent nonlinearity in steady-state pharmacokinetics of
pharmacological doses of folic acid.
Another mechanism may involve downregulation of the
intestinal and/or renal transporters that are responsible for
folate absorption and reabsorption, respectively. Using the
Caco-2 cell line model of the intestinal epithelium and HK-
2 cells (proximal renal tubule epithelial cells), Ashokkumar
and colleagues observed that carrier-mediated uptake of
tritiated folic acid by Caco-2 and HK-2 cells maintained in
folate-oversupplemented media was signiﬁcantly and specif-
ically lower compared to cells maintained in folate-suﬃcient
media [20, 23]. This was accompanied by signiﬁcantly
lower levels of RFC and PCFT protein in both intestinal
and renal epithelial cells and of folate receptor protein in
renal epithelial cells. This downregulation appeared to be
mediated in part via a transcriptional mechanism, as mRNA
transcript levels and promoter activity were lower in folate-
oversupplemented cells. The reduction in folate receptor
protein is of particular interest to this discussion because it
is unique among the three proteins studied in that it has a
higher aﬃnity for folic acid than it does for reduced folates
[52]. At least one-quarter of a 4mg dose of folic acid is
excretedunchangedasaresultofexceedingtherenalcapacity
for reabsorption, which is mediated by the folate receptor
[53]. This would be exacerbated by a reduction in folate
receptor expression and might oﬀer a partial explanation for
the absence of signiﬁcantly higher levels of circulating folic
acid in 5mg group.
As the PCFT and folate receptor are also expressed
in peripheral tissues, downregulation of these transporters
would theoretically lead to decreased cellular uptake of folic
acid. Although this would lead to higher concentrations of
unmetabolized folic acid in plasma, it would also predict
a larger proportion of the dose being available for renal
excretion. This may be compounded by saturation of cellular
folate pools under conditions of high folate intake; as cellular
folateconcentrationsincrease,thereisincreasedcompetition
for FPGS and the marginal formation of polyglutamates
decreases [54]. Under these conditions, only a small propor-
tion of folate that enters the cell is retained and the majority
is released back into plasma.
In the primary analysis of this trial, Nguyen and
colleagues found that women receiving the 5mg dose of
folic acid achieved signiﬁcantly higher plasma and RBC
total folate concentrations compared to women receiving the
1.1mg dose [22]. This, together with our ﬁnding that unme-
tabolized folic acid concentrations were not signiﬁcantly
higher, suggests that the higher total folate concentrations
achieved with the 5mg dose of folic acid constitute reduced,
coenzymatic folates. Therefore, upregulation of DHFR, as
described in the previous section, may be another mech-
anism by which exposure to unmetabolized folic acid was
regulated among women in the 5mg group.
It is clear that folic acid supplementation is important
for planning and pregnant women. What is not clear,
however, is the optimal dose of folic acid needed for the
prevention of NTDs and other folate-dependent congenital
malformations. Current guidelines advise all women who
“could become pregnant” to consume a daily multivitamin
providing 0.4mg to 1mg of folic acid; a woman deemed to
have personal characteristics or health conditions associated
with an elevated risk of having a baby with an NTD may be
advised to consume a higher dose of folic acid, depending on
her contemporaneous folate status. However, there is a lack
of research on the pharmacokinetics and safety of high-dose
folic acid supplementation.
Folic acid is generally considered to be safe at doses up
to 1mg/day and there is little evidence to show that doses up
to 5mg/day are harmful to healthy adults. In recent years,
however, there has been increasing concern that exposure
to unmetabolized folic acid, which results from folic acid
intakes that overwhelm the body’s metabolic capacity, may
be associated with adverse eﬀects.
In Canada, legislation mandating fortiﬁcation of
enriched cereal grains with folic acid was introduced in
1998, resulting in universal increases in folic acid intakes and
folate concentrations in the blood. In addition to consuming
folic acid-fortiﬁed foods, many women also consume
supplements containing folic acid, thus it is important to
develop a better understanding of the relationship between
unmetabolized folic acid and dietary and biochemical
indicators of folate status and the eﬀect of supplementation.
In this study, we evaluated plasma unmetabolized folic
acid in relation to dietary folate intake, blood total folate
concentration, and the eﬀect of supplementation among
healthy women of reproductive age using plasma samples
collected from a randomized trial comparing 30 weeks of
supplementation with 1.1mg or 5mg of folic acid per day.
To the best of our knowledge, this was the ﬁrst clinical
trial that was conducted for the purpose of evaluating the
pharmacokinetics of high-dose folic acid supplementation in
this population and the data presented herein are the ﬁrst toObstetrics and Gynecology International 15
describe the folic acid status of women of reproductive age in
a folic acid-fortiﬁed population.
In this study, we found that unmetabolized folic acid is
present at low levels in the majority of women who do not
consume folic acid supplements but who do consume folic
acid-fortiﬁed foods. Contrary to our original hypothesis,
however,therewasnosigniﬁcantcorrelationbetweenplasma
folic acid and dietary folic acid or total folate intake or
between plasma folic acid and plasma or RBC total folate in
samples collected at baseline (i.e., before supplementation).
The former may reﬂect imprecision in our method of
dietary assessment and the relatively restricted range of
folic acid intakes in our population. On the other hand,
the latter suggests that the ability to metabolize folic acid
to reduced derivatives is highly variable and that this may
be a more important determinant of systemic exposure to
unmetabolized folic acid.
Upon initiation of supplementation, we observed a
signiﬁcant increase in the proportion of women who had
detectable levels of unmetabolized folic acid in fasting
plasma samples; however, the increase was not sustained.
A similar rise and fall was observed in the concentrations
of unmetabolized folic acid over the 30-week supplemen-
tation period; however, the increase in plasma folic acid
over the ﬁrst 12 weeks of supplementation did not reach
statistical signiﬁcance. After 30 weeks of supplementation,
both the proportion of women with detectable folic acid
and concentrations of folic acid returned to levels that were
not signiﬁcantly diﬀerent compared to baseline. For both
measures, there were no signiﬁcant diﬀerences between the
women receiving the 1.1mg dose and those receiving the
5mg dose. These data suggest that there are homeostatic
mechanisms that limit systemic exposure to circulating folic
acid, such as downregulation of carrier-mediated transport
systems and upregulation of folic acid metabolism.
Taken together with data previously published by our
group, it appears that women who supplement daily with
5mg of folic acid achieve higher plasma and RBC total
folate concentrations compared to women who supplement
with 1.1mg/day without an apparent increase in exposure
to unmetabolized folic acid. This further suggests that the
higher plasma and RBC total folate concentrations achieved
with the 5mg dose of folic acid represent reduced, coenzy-
matic folate; however, additional studies will be needed to
conﬁrm.
Insummary,thisworkbothcorroboratesandcontradicts
current and common views on folic acid metabolism. For
instance, hepatic DHFR activity in humans is considered
to be highly variable but universally low. The variation in
unmetabolized folic acid concentrations before and during
supplementation that we observed supports the notion that
hepatic metabolic capacity is highly variable; however, for
many women in the present study, plasma concentrations
of unmetabolized folic acid remained low even though they
were consuming 2.5- to 12.5-times the daily dose that was
previously shown to produce a sustained appearance of folic
acid in plasma. For these women, it would appear that
concerns surrounding excessive exposure to unmetabolized
folic acid with the 5mg dose may be unwarranted; thus
further consideration could be given to the high-dose folic
acid strategy for the primary prevention of NTDs even in the
absence of the standard risk factors. On the other hand, until
more is known about the safety of exposure to unmetabo-
lized folic acid, alternative approaches to achieving optimally
protective folate concentrations could be considered for
women who have a lower capacity to handle folic acid. One
alternative could be supplementation with levomefolic acid
(the calcium salt of 5-CH3H4PteGlu).
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